Evidence map›Paper›PMID 36043776›Full record

ArticleCurrent neurovascular research2022

P2RY12 Increased Neuroinflammation to Accelerate Depression-like Behaviors by the NLPR3 Inflammasome.

Jie Liu, Enyan Yu

Abstract read
PubMed Publisher
In one paragraph

Article in Current neurovascular research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 61% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Jie LiuThe Second Clinical Medical College of Zhejiang Chinese Medical University, Hanzhou 310053, China.
Enyan YuDepartment of Clinical Psychology, Zhejiang Cancer Hospital, Hanzhou 310012, China.
Zhejiang Cancer Hospital · CNZhejiang Chinese Medical University · CN

Funding

National Natural Science Foundation of China 8177051246
6 · The paper itself

Abstract

introductionDepression is a class of important mental illness, which has become a severe health problem perplexing the world due to its high morbidity rate, high disability rate, and great disease burden. This study aimed to evaluate the role and possible mechanisms of P2RY12 in the depression-like behaviors model.

methodsSerum samples of patients with depression-like behaviors were used to analyze the expression of P2RY12. Models of mice were given LPS via intraperitoneal injection for 7 days. Behavioral tests were executed in this experiment.

resultsThe expression of P2RY12 in models of depression-like behaviors or mice with depression- like behaviors were induced. The inhibition of P2RY12 presents depression-like behaviors and reduces inflammation in the model of depression-like behaviors. P2RY12 induced NLRP3 expression and suppressed NLRP3 ubiquitination in a model of depression-like behavior. The inhibition of NLRP3 reduced the effects of P2RY12 in mice model of depression-like behaviors. The regulation of NLRP3 controlled the effects of the P2RY12 in vitro model of depression-like behaviors.

conclusionWe conclude that P2RY12 increased neuroinflammation to accelerate depression-like behaviors by NLPR3 inflammasome, providing novel information for the treatment of depressionlike behaviors.

Indexed as

DepressionInflammasomesAnimalsInflammationLipopolysaccharidesMiceNeuroinflammatory DiseasesNLR Family, Pyrin Domain-Containing 3 ProteinReceptors, Purinergic P2Y12InflammasomesLipopolysaccharidesNLR Family, Pyrin Domain-Containing 3 ProteinP2ry12 protein, mouseReceptors, Purinergic P2Y12depression-like behaviorsneurotrophilsNLPR3P2RY12proinflammatory cytokineubiquitination

Identifiers

PMID36043776
OpenAlexW4293548330

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.